S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
AI Stock Caught Trading Under Secret Name (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
AI Stock Caught Trading Under Secret Name (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
AI Stock Caught Trading Under Secret Name (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
AI Stock Caught Trading Under Secret Name (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

$2.87
-0.13 (-4.33%)
(As of 02/21/2024 ET)
Today's Range
$2.85
$2.99
50-Day Range
$2.47
$3.12
52-Week Range
$1.95
$4.53
Volume
7,713 shs
Average Volume
8,751 shs
Market Capitalization
$23.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Lisata Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
422.6% Upside
$15.00 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.32mentions of Lisata Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.91) to ($2.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.70 out of 5 stars

Medical Sector

396th out of 932 stocks

Pharmaceutical Preparations Industry

182nd out of 429 stocks


LSTA stock logo

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

LSTA Stock Price History

LSTA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Lisata Therapeutics Inc LSTA
Q3 2023 Lisata Therapeutics Inc Earnings Call
Earnings Preview: Lisata Therapeutics
See More Headlines
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LSTA
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+422.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-54,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.44 per share

Miscellaneous

Free Float
6,381,000
Market Cap
$23.36 million
Optionable
Not Optionable
Beta
0.97
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 67)
    B.Sc. (Hons.), M.Sc., Ph.D., President, CEO & Director
    Comp: $1.16M
  • Dr. Kristen K. Buck M.D. (Age 50)
    Executive VP of R&D and Chief Medical Officer
    Comp: $938.42k
  • Mr. James Nisco
    VP of Finance & Treasury
  • Mr. Tariq Imam
    Vice President of Business Development & Operations and Corporate Counsel
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    Vice President of Investor Relations & Corporate Communications
  • Ms. Gail Holler (Age 65)
    Vice President of Human Resources
  • Dr. William K. Sietsema Ph.D. (Age 68)
    Vice President of Global Regulatory Affairs
    Comp: $350.55k














LSTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lisata Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LSTA shares.
View LSTA analyst ratings
or view top-rated stocks.

What is Lisata Therapeutics' stock price target for 2024?

1 brokers have issued 12 month target prices for Lisata Therapeutics' stock. Their LSTA share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 422.6% from the stock's current price.
View analysts price targets for LSTA
or view top-rated stocks among Wall Street analysts.

How have LSTA shares performed in 2024?

Lisata Therapeutics' stock was trading at $2.73 at the start of the year. Since then, LSTA shares have increased by 5.1% and is now trading at $2.87.
View the best growth stocks for 2024 here
.

Are investors shorting Lisata Therapeutics?

Lisata Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 10,600 shares, a decrease of 83.0% from the January 15th total of 62,400 shares. Based on an average trading volume of 15,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.2% of the shares of the stock are sold short.
View Lisata Therapeutics' Short Interest
.

When is Lisata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our LSTA earnings forecast
.

Who are Lisata Therapeutics' major shareholders?

Lisata Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (3.31%), Citadel Advisors LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LSTA) was last updated on 2/22/2024 by MarketBeat.com Staff